$1.33 Billion in Sales Expected for Zoetis Inc (ZTS) This Quarter

Equities research analysts expect that Zoetis Inc (NYSE:ZTS) will post sales of $1.33 billion for the current quarter, according to Zacks. Three analysts have provided estimates for Zoetis’ earnings. The highest sales estimate is $1.35 billion and the lowest is $1.31 billion. Zoetis posted sales of $1.23 billion during the same quarter last year, which suggests a positive year over year growth rate of 8.1%. The company is scheduled to report its next quarterly earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Zoetis will report full-year sales of $1.33 billion for the current year, with estimates ranging from $5.68 billion to $5.77 billion. For the next year, analysts anticipate that the firm will report sales of $6.03 billion per share, with estimates ranging from $5.90 billion to $6.10 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Zoetis.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.03. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. Zoetis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.47 earnings per share.

Several brokerages have weighed in on ZTS. Deutsche Bank increased their price objective on Zoetis from $76.00 to $78.00 and gave the company a “hold” rating in a report on Friday, February 16th. Piper Jaffray Companies set a $88.00 price objective on Zoetis and gave the company a “buy” rating in a report on Friday, February 16th. Bank of America increased their price objective on Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a report on Friday, February 16th. Stifel Nicolaus reissued a “buy” rating and set a $86.00 price objective (up from $84.00) on shares of Zoetis in a report on Friday, February 16th. Finally, BMO Capital Markets set a $78.00 price objective on Zoetis and gave the company a “hold” rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $79.83.

In related news, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares in the company, valued at approximately $4,044,437.38. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Chemical Bank purchased a new stake in shares of Zoetis in the fourth quarter worth $350,000. Cambridge Investment Research Advisors Inc. raised its position in shares of Zoetis by 27.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock worth $1,288,000 after buying an additional 3,904 shares in the last quarter. Xact Kapitalforvaltning AB raised its position in shares of Zoetis by 9.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock worth $5,051,000 after buying an additional 6,253 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Zoetis by 31.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock worth $9,719,000 after buying an additional 32,149 shares in the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA raised its position in shares of Zoetis by 106.2% in the fourth quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock worth $1,807,000 after buying an additional 12,925 shares in the last quarter. Institutional investors own 94.18% of the company’s stock.

Zoetis (NYSE:ZTS) traded up $2.03 during mid-day trading on Tuesday, hitting $82.79. The stock had a trading volume of 2,662,714 shares, compared to its average volume of 3,080,078. The company has a market capitalization of $39,980.00, a price-to-earnings ratio of 37.98, a PEG ratio of 1.81 and a beta of 1.07. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. Zoetis has a 52 week low of $52.25 and a 52 week high of $82.93.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.61%. Zoetis’s dividend payout ratio is currently 22.94%.

COPYRIGHT VIOLATION WARNING: “$1.33 Billion in Sales Expected for Zoetis Inc (ZTS) This Quarter” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://weekherald.com/2018/02/23/1-33-billion-in-sales-expected-for-zoetis-inc-zts-this-quarter.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply